Latest news with #ShwetaJalan
The Hindu
7 hours ago
- Business
- The Hindu
Advent to invest $175 million in Felix Pharma to acquire minority stake
Advent, a private equity investor, has announced that funds managed by it have signed a definitive agreement to invest $175 million via primary and secondary capital for a significant minority stake in Dublin, Ireland-based Felix Pharmaceuticals Pvt. Ltd. (Felix), a global Gx animal pharma player. Felix Pharma is one of the developers and manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded Gx players for private labelling, particularly in the U.S. Shweta Jalan, Managing Partner, Advent, said, 'Healthcare has been a long-standing focus for us, and strong parallels we see between success in human Gx globally and emerging opportunity in animal health Gx. Felix is well positioned to lead this space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities.' 'Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' she added, Founded in 2015 by Neeraj Agrawal, a McKinsey alum, Sir Jonathan Symonds, Chair of GSK and with 30 years of experience in global pharmaceuticals, and Dr. Shumeet Banerji, ex-CEO of Booz-Allen, Felix said it has pursued strategic growth through a disciplined approach, While the company achieved its first U.S. FDA approval in 2020, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline. It has a USFDA-approved oral solid facility dedicated to animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder, Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger. Advent's strong track record in healthcare and pharma, and their close involvement in building strong businesses, gives us great confidence.'
&w=3840&q=100)
Business Standard
17 hours ago
- Business
- Business Standard
Advent to invest $175 million in animal health drugmaker Felix Pharma
The deal, which includes both primary and secondary transactions, positions Felix to accelerate its global ambitions as a differentiated player in the nascent but expanding companion animal generics Jaden Mathew Paul Alappuzha Private equity firm Advent International is set to invest $175 million in Felix Pharmaceuticals, securing a minority stake in the Dublin-based company that specialises in off-patent medicines for pets. The deal, which includes both primary and secondary transactions, positions Felix to accelerate its global ambitions as a differentiated player in the nascent but expanding companion animal generics space. The company expects to commission a new injectable facility by the third quarter of 2025, adding to its USFDA-approved oral solid manufacturing plant. 'Healthcare has been a long-standing focus for us, and strong parallels we see between success in human Gx globally and emerging opportunity in animal health Gx,' said Shweta Jalan, managing partner, Advent. 'Felix is well positioned to lead this space,' said Jalan, adding, 'Its rapid growth and high customer satisfaction make it a differentiated platform.' Less than 10 per cent of the companion animal market is currently held by generic players, said Pankaj Patwari, managing director, Advent. The company develops bio-equivalent generics across a wide range of therapeutic categories, including NSAIDs, antibacterials, and antiparasitics, for dogs, cats, and horses. 'We were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger,' said Agrawal. Felix has offices in Kansas City and Gurugram, alongside its Dublin headquarters, and employs around 500 people globally.
